(Q45752089)

15 December 2017

title

Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells (English)

1 reference

15 December 2017

author

Brian Druker

3

1 reference

15 December 2017

author name string

M MacPartlin

1

1 reference

15 December 2017

A M Smith

2

1 reference

15 December 2017

L A Honigberg

4

1 reference

15 December 2017

M W Deininger

5

1 reference

15 December 2017

publication date

12 June 2008

1 reference

15 December 2017

published in

Leukemia

1 reference

15 December 2017

volume

22

1 reference

15 December 2017

issue

7

1 reference

15 December 2017

page(s)

1354-1360

1 reference

15 December 2017

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Reversibility of acute B-cell leukaemia induced by BCR-ABL1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

New insights into the regulation and functions of Tec family tyrosine kinases in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Engagement of the human pre-B cell receptor generates a lipid raft-dependent calcium signaling complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Phosphorylation of Bruton's tyrosine kinase by c-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Production of high-titer helper-free retroviruses by transient transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Critical role for Gab2 in transformation by BCR/ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Autoinhibition of Bcr-Abl through its SH3 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

Tec kinases: a family with multiple roles in immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

inferred from DOI database lookup

7 January 2021

based on heuristic

Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.126

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2008.126

1 reference

15 December 2017

Dimensions Publication ID

1003607640

0 references

1 reference

15 December 2017